OTC HYDROCORTISONE 1% MARKETING WILL BE SUBJECT TO "IMMEDIATE"
Executive Summary
OTC HYDROCORTISONE 1% MARKETING WILL BE SUBJECT TO "IMMEDIATE" regulatory action until FDA lifts its OTC marketing hold, the agency told representatives of the Nonprescription Drug Manufacturers Association at an April 4 meeting. FDA said it would take "immediate action" against "any manufacturer marketing [a hydrocortisone 1% products] OTC before the agency gives an authorization to everyone to do so," according to minutes of the meeting. FDA said it would "most likely" authorize OTC marketing in a "subsequent notice in the Federal Register." "It is important that all companies respect the temporary marketing-hold status and have an equal opportunity to enter the marketplace at the same time," FDA said it told the NDMA representatives." FDA also told NDMA that "early marketing" of an OTC 1% hydrocortisone product "would give the agency the wrong signal and could be detrimental to future proposed switches." FDA published a notice of proposed rulemaking in the Federal Register on Feb. 27 announcing the Rx-to-OTC switch of 0.5-1% hydrocortisone formulations ("The Pink Sheet" March 5, p. 3). However, the notice specified that marketing could not begin until FDA's official okay. The agency reiterated to NDMA that it intends to review all comments on the proposed switch before reaching a decision "as to whether OTC marketing can begin before publication of the final monograph for OTC external drug products." NDMA, which requested the meeting with FDA, told the agency there is "a lot of interest among their member companies as to when OTC marketing would be allowed to begin," the minutes note. FDA will be accepting comments, objections and requests for oral hearings on the Rx-to-OTC switch until April 30. The agency told NDMA it expected that "revisions in proposed labeling may be indicated based on the comments received." However, FDA said "very few" comments have been received to date. Taking part in the discussion from NDMA were association President James Cope and VP-Scientific Affairs William Soller. Representing FDA were OTC Drug Evaluation Director William Gilbertson, OTC Drug Evaluation Deputy Director Gerald Rachanow, Office of Compliance Deputy Director Sammie Young, and Lee Geismar, Chief of the Analgesic, Antiperspirant & Antimicrobial Branch. A member of the British Pharmacopiea, in comments to the OTC external analgesics monograph, provided additional support for the 1% hydrocortisone Rx-to-OTC switch. In a letter to FDA, Malcom Greaves, MD, University of London, said that in four years of OTC marketing in the U.K. there has been no increase in adverse events.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth